Compare SSKN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSKN | AYTU |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 23.4M |
| IPO Year | 2005 | N/A |
| Metric | SSKN | AYTU |
|---|---|---|
| Price | $1.30 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $9.33 |
| AVG Volume (30 Days) | 100.2K | ★ 130.1K |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $30,980,000.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.74 | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $0.95 |
| 52 Week High | $3.86 | $3.07 |
| Indicator | SSKN | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 56.45 |
| Support Level | $1.18 | $2.60 |
| Resistance Level | $1.33 | $2.85 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 24.32 | 25.53 |
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.